Cellular uptake and infection by canine parvovirus involves rapid dynamin-regulated clathrin-mediated endocytosis, followed by slower intracellular trafficking.
Canine parvovirus (CPV) is a small, nonenveloped virus that is a host range variant of a virus which infected cats and changes in the capsid protein control the ability of the virus to infect canine cells. We used a variety of approaches to define the early stages of cell entry by CPV. Electron microscopy showed that virus particles concentrated within clathrin-coated pits and vesicles early in the uptake process and that the infecting particles were rapidly removed from the cell surface. Overexpression of a dominant interfering mutant of dynamin in the cells altered the trafficking of capsid-containing vesicles. There was a 40% decrease in the number of CPV-infected cells in mutant dynamin-expressing cells, as well as a approximately 40% decrease in the number of cells in S phase of the cell cycle, which is required for virus replication. However, there was also up to 10-fold more binding of CPV to the surface of mutant dynamin-expressing cells than there was to uninduced cells, suggesting an increased receptor retention on the cell surface. In contrast, there was little difference in virus binding, virus infection rate, or cell cycle distribution between induced and uninduced cells expressing wild-type dynamin. CPV particles colocalized with transferrin in perinuclear endosomes but not with fluorescein isothiocyanate-dextran, a marker for fluid-phase endocytosis. Cells treated with nanomolar concentrations of bafilomycin A1 were largely resistant to infection when the drug was added either 30 min before or 90 min after inoculation, suggesting that there was a lag between virus entering the cell by clathrin-mediated endocytosis and escape of the virus from the endosome. High concentrations of CPV particles did not permeabilize canine A72 or mink lung cells to alpha-sarcin, but canine adenovirus type 1 particles permeabilized both cell lines. These data suggest that the CPV entry and infection pathway is complex and involves multiple vesicular components.
Parker
J S
JS
James A. Baker Institute for Animal Health, College of Veterinary Medicine, Cornell University, Ithaca, New York 14853, USA.
Parrish
C R
CR
D006516:Adenoviruses, Canine / Q000502:physiology; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000914:Antibodies, Viral / Q000276:immunology; D001692:Biological Transport; D002453:Cell Cycle; D002462:Cell Membrane / Q000821:virology; D002463:Cell Membrane Permeability; D002467:Cell Nucleus; D002966:Clathrin / Q000378:metabolism*; D003034:Coated Pits, Cell-Membrane / Q000648:ultrastructure / Q000821:virology; D003911:Dextrans / Q000378:metabolism; D004285:Dogs; D034281:Dynamins; D004705:Endocytosis / Q000502:physiology*; D004722:Endoribonucleases / Q000378:metabolism / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005656:Fungal Proteins; D020558:GTP Phosphohydrolases / Q000378:metabolism*; D007424:Intracellular Fluid / Q000378:metabolism; D018942:Macrolides; D008854:Microscopy, Electron; D016296:Mutagenesis; D009500:Neutralization Tests; D017993:Parvovirus, Canine / Q000378:metabolism* / Q000502:physiology / Q000648:ultrastructure; D006180:Proton-Translocating ATPases / Q000037:antagonists & inhibitors; D013997:Time Factors; D014168:Transferrin / Q000378:metabolism; D014771:Virion / Q000378:metabolism
D000900:Anti-Bacterial Agents; D000914:Antibodies, Viral; D002966:Clathrin; D003911:Dextrans; D004791:Enzyme Inhibitors; D005656:Fungal Proteins; D018942:Macrolides; D014168:Transferrin; C014801:alpha-sarcin; C040929:bafilomycin A1; D004722:Endoribonucleases; D020558:GTP Phosphohydrolases; D006180:Proton-Translocating ATPases; D034281:Dynamins